Sonoma Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $4.31M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2019 Ended Sep 30, 2018 | Nov 8, 2018 | After market close | – | – | – |
| Q1 FY2019 Ended Jun 30, 2018 | Aug 8, 2018 | After market close | – | – | – |
| Q4 FY2018 Ended Mar 31, 2018 | Jun 13, 2018 | After market close | – | – | – |
| Q3 FY2018 Ended Dec 31, 2017 | Feb 7, 2018 | After market close | – | – | – |
| Q2 FY2018 Ended Sep 30, 2017 | Nov 9, 2017 | After market close | – | – | – |
| Q1 FY2018 Ended Jun 30, 2017 | Aug 8, 2017 | After market close | – | – | – |
| Q4 FY2017 Ended Mar 31, 2017 | Jun 5, 2017 | After market close | – | – | – |
| Q3 FY2017 Ended Dec 31, 2016 | Feb 9, 2017 | After market close | – | – | – |
| Q2 FY2017 Ended Sep 30, 2016 | Nov 10, 2016 | After market close | – | – | – |
| Q1 FY2017 Ended Jun 30, 2016 | Jul 28, 2016 | After market close | – | – | – |
| Q4 FY2016 Ended Mar 31, 2016 | Jun 16, 2016 | After market close | – | – | – |
| Q3 FY2016 Ended Dec 31, 2015 | Feb 4, 2016 | After market close | – | – | – |
Press releases
Announcements Sonoma Pharmaceuticals filed with the SEC
Pharmaceuticals Announces Pricing of $4 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
SONOMA PHARMACEUTICALS, INC. INVESTOR PRESENTATION
Other events · EX-99.1 to Form 8-K
Sonoma Pharmaceuticals, Inc. Investor Presentation September 2025
Other events · EX-99.1 to Form 8-K
Sonoma Pharmaceuticals, Inc. Investor Presentation April 2025
Other events · EX-99.1 to Form 8-K
INVESTOR PRESENTATION AS OF APRIL 7, 2025
Other events · EX-99.1 to Form 8-K
INVESTOR PRESENTATION AS OF OCTOBER 22, 2024.
Material agreement · Other events · EX-99.1 to Form 8-K
1-for-20 Reverse Split of Outstanding Common Stock
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
INVESTOR PRESENTATION AS OF APRIL 9, 2024.
Regulation FD disclosure · EX-99.1 to Form 8-K
Sonoma Pharmaceuticals, Inc. Investor Presentation April 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Sonoma Pharmaceuticals, Inc. Investor Presentation January 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Sonoma Pharmaceuticals, Inc. Investor Presentation October 2023
Other events · EX-99.1 to Form 8-K/A
Sonoma Pharmaceuticals, Inc. Investor Presentation October 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
INVESTOR PRESENTATION AS OF MAY 10, 2023.
Regulation FD disclosure · EX-99.1 to Form 8-K
Sonoma Pharmaceuticals, Inc. January 202 3
Regulation FD disclosure · EX-99.1 to Form 8-K
Sonoma Pharmaceuticals, Inc. NASDAQ: SNOA January 2022
Regulation FD disclosure · EX-99.1 to Form 8-K